Fig. 5

M1-21 inhibited cancer proliferation and metastasis in wild-type mice. A The FVB/N MMTV-PyVT mice (female, 8 weeks old, beginning to form spontaneous breast cancer) were injected intraperitoneally with PBS (Control, n = 4) or M1-21 (20 mg/kg, n = 7) once daily for 28 days. B Cancer tissue was harvested on Day 29 for imaging. The weight of cancer tissue was measured for GraphPad analysis. C The representative sections of the cancer samples of panel A were immunostained with anti-KI-67 antibody (1:200), and anti-CDC25B antibody (1:200) followed by microscope imaging (200×, Nikon TE2000). Scale bar: 200 μm. D Wild-type BALB/c mice were tail-vein injected with 4T1-Luc-GFP cells (1 × 10^6 cells/mouse). Three days later, the mice were randomly divided into three groups, followed by intraperitoneal PBS injection (Control, n = 6), M1-21 (15 mg/kg, n = 6), or M1-21 (30 mg/kg, n = 6) every two days throughout the experiment. In vivo imaging of mice was performed by intraperitoneal injection of D-Luciferin potassium salt (3 mg/200 mL/mouse) at various post-treatment time points M1-21 (Day 1, Day 7, and Day 17) and then photographs were taken by the IVIS Lumina XR machine. Bright red fluorescence signals represented the amount of luciferase-labeled 4T1 cells in mice. E Different organs of representative mice were harvested on Day 21 and fluorescent imaging was performed as described above. F The D panel mouse survival statistic curves were obtained by the Mantel-Cox estimator with log rank test